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98.6% of patients had 2 or more fractures after age 40 years, the mean (SD) number 
of fractures was 4.2 (1.7) and median number was 4.0 (interquartile range 3.0–5.0). 
During the study, the mean (SD) duration of treatment by teriparatide was 443 (203) 
days; at the end of 17th month, 67.9% of patients were still on treatment. The main 
reasons of treatment discontinuation were treatment completion (69.9%), adverse 
events (14.5%), patient decision (14.0%), and physician decision (2.2%). Between 
baseline and end of study, the rate of women with back pain decreased from 93.8% 
to 83.3% and 57.1% had an improvement in the severity, mean (SD) back pain 
intensity VAS decreased from 55.9 (24.8) to 35.0 (24.2), and mean (SD) EQ-5D VAS 
increased from 52.6 (19.4) at baseline to 57.8 (21.4) at end of study. CONCLUSIONS: 
French patients with severe osteoporosis treated with teriparatide in a routine setting 
had an increase in quality of life and a decrease in back pain during the teriparatide 
treatment period and post-treatment follow-up. The results should be interpreted in 
the context of a non-controlled observational study.
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BACKGROUND: The prevalence of sleep disturbances and fatigue among patients 
with rheumatoid arthritis (RA) is high. TNF therapy reduces disease activity and dis-
ability in RA, but few studies have analyzed the impact of TNF vs. traditional 
DMARD therapy, sociodemographic and clinical factors on sleep and fatigue, in 
prospective cohorts. OBJECTIVES: We assessed the effect of TNF therapy, sociode-
mographic and clinical factors on sleep disturbances and fatigue in RA patients. 
METHODS: A total of 1,082 RA patients from the NDB-Portugal cohort participated 
in this prospective study. Patients´ last observation was used. Univariate (UV) and 
multivariate (MV) linear regression models (β, 95% CI) assessed the impact of the 
following on sleep disturbances (measured by the sleep disturbance scale (VAS 0–10, 
10 is worst) and the insomnia severity index (0–28, 28 is worst)) and fatigue (fatigue 
scale (VAS 0–10,10 is worst)): traditional DMARD and TNF therapy, age, sex, educa-
tion level, marital status, number of major comorbidities, RA duration, disability 
(HAQ 0–3, 3 is worst), quality of life (VASQOL 0–1, 1 is better), emotional distress 
(Hospital Anxiety and Depression Scale—HADS 0–21, 21 is worst) and prednisone 
use. RESULTS: In MV, TNF therapy seemed to decrease fatigue (−0.60 (−1.08, −0.11)) 
when compared to traditional DMARDs and although not statistically signiﬁ cant, 
decreased sleep disturbances (−0.46 (−1.04, 0.13)) and insomnia (−0.22 (−1.16, 0.73)). 
An increase in sleep disturbances was seen with worse HAQ (0.64 (0.25, 1.02)), lower 
VASQOL: (−1.46 (−2.63, −0.28)), more anxiety symptoms: (0.19 (0.09, 0.29)) and 
higher fatigue (0.26 (0.17, 0.36)). These results were also seen for insomnia and 
fatigue. More sleep disturbances (0.18 (0.12, 0.25)) increased fatigue and higher 
fatigue increased insomnia (0.39 (0.23, 0.54)). CONCLUSIONS: We found that the 
use of TNF therapy improved fatigue when compared to traditional DMARDs. Higher 
disability and worse quality of life increased sleep disturbances, insomnia and fatigue.
PMS60
TNF THERAPY REDUCES THE ODDS OF WORSENING DISABILITY 
TRENDS IN RHEUMATOID ARTHRITIS OVER AT LEAST 2 YEARS—DATA 
FROM THE NDB-PORTUGAL COHORT
Pedro S1, Vasconcelos J1, Marques R1, Chaves I1, Rodrigues A1, Michaud K2, Wolfe F3, 
Garcia E1
1BioEPI, Clinical and Translational Research Center, Oeiras, Portugal; 2University of Nebraska 
Medical Center, Omaha, NE, USA; 3National Databank for Rheumatic Diseases, Wichita, KS, 
USA
OBJECTIVES: Many studies have identiﬁ ed predictors of the health assement ques-
tionnaire (HAQ), but few have evaluated the predictors of HAQ trends among RA 
patients. To investigate the predictors of worsening disability trends compared to other 
patterns among RA patients over at least 2 years. METHODS: A total of 646 RA 
patients from the ongoing biannual NDB-Portugal cohort with at least four consecu-
tive HAQ scores per patient during their follow-up were used.The proportion deﬁ ned 
by the number of 6-month positive increments in HAQ scores (worsening function) 
divided by the total number of differences was computed per patient and used to deﬁ ne 
a patient’ trend. The outcome was then deﬁ ned as the presence of a trend of worsening 
disability (when proportion >0.5). This meant that a patient’s tendency of worsening 
was higher than their tendency of improving during their own follow-up. Univariate 
(UV) and multivariate (MV) generalized estimating equations (GEE) were used to 
study the predictors of a worsening disability trend. Age, education, disease duration, 
paid work, retirement, number of total major comorbidities, SF-36 mental component, 
RADAI, the VAS scales of sleep, fatigue and pain, the use of current TNF (with or 
without concomitant DMARDs) vs. traditional DMARD therapy and steroids, were 
used as possible predictors. RESULTS: A total of 26% patients had worsening dis-
ability trends. The UV analyses showed that all of the following factors were statisti-
cally relevant: age, educational level, number of major comorbidities, sleep disturbances 
and fatigue, RADAI and the use of TNF therapy. The ﬁ nal MV model included pain 
(OR: 1.003 (95%CI: (1.000; 1.005))), age (OR: 1.02 (1.01; 1.02)) and the use of TNF 
(OR: 0.94 (0.91; 0.97)). CONCLUSIONS: In our study, we showed that older age 
and more pain predicted worsening HAQ disability trends. The use of TNF therapy 
was the only factor that decreased the odds of having a worsening HAQ trajectory.
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OBJECTIVES: To establish a conceptual model which relates osteoarthritis (OA) 
affectation, functional disability in daily activities, and Quality of Life (QoL). 
METHODS: The present is an observational, cross-sectional, multicenter study. OA 
presence/absence, by location, was clinically recorded. Disability was assessed with 
the Health Assessment Questionnaire Disability Index (HAQ-DI), QoL through the 
EuroQoL-5D questionnaire. Descriptives were used for sociodemographic and clinical 
variables; relationship between OA, disability and QoL was estimated through Struc-
tural Equation Modeling (SEM). This multivariate analysis technique allows to 
hypothesize multiple relationships among latent, unobserved variables and tests the 
model with a equation system. RESULTS: A total of 965 OA patients were included 
[mean age = 64 years (SD = 11); 75% women]. Mean body locations affected by OA 
was 2.81 (median = 2; SD = 1.613). The most frequently affected locations were knees 
(67% of the patients), lumbar (60%) and cervical (45%) spine. Regarding EuroQoL-
5D, most patients reported not having severe problems in the ﬁ ve areas assessed. 
‘Other activities’ (mean = 1.172; SD = 0.957) and ‘reach’ (mean = 1.127; SD = 0.912) 
were the HAQ-DI categories that showed higher disability. The SEM presented OA, 
disability and QoL as latent, related variables. 92% of QoL was accounted for dis-
ability (R-squared = 0.92). The global model that depicts OA as causing disability, 
and disability affecting QoL, has a marginal adjustment (CMIN/DF = 5.42; RMR = 
0.026; RMSEA = 0.069). CONCLUSIONS: With the available data, the functional 
disability can account for the decrease in QoL. Theoretically, OA is strongly related 
with disability and QoL, but the model fails to fully explain this link. As statistical 
techniques need good measurement models to correctly estimate relationships, stan-
dard clinical records seem insufﬁ cient for this purpose. Additional valid measurements 
of OA affectation would be needed, to give evidence of its direct effect on disability 
and QoL.
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OBJECTIVES: To evaluate the impact of certolizumab pegol (CZP) monotherapy on 
household work and daily activities in RA patients over 2 years. METHODS: Patients 
in the FAST4WARD Phase III trial were randomised to CZP 400 mg administered 
every 4 weeks (Q4W) or placebo for 24 weeks. Those who completed or withdrew 
at/after Week 12 were eligible to enter an open-label extension (OLE) study of CZP 
400 mg Q4W. This analysis focuses on CZP completers who entered the OLE study 
and had 2 years (100 weeks) of CZP exposure from baseline (BL). Household pro-
ductivity and impact on family/social/leisure activities were assessed using the vali-
dated Work Productivity Survey (WPS-RA). Analyses were conducted on observed 
data. FAST4WARD:NCT00548834; OLE:NCT00160693. RESULTS: Sixty-nine 
CZP completers entered the OLE. At BL: mean disease duration: 9.5 years; mean 
HAQ-DI: 1.42; mean DAS28-3(CRP): 5.76. Burden of RA on household productivity 
at BL was substantial: mean 10.1 household work days missed/month, mean 12.1 
household work days with reduced productivity/month, mean 5 days missed/month 
of family/social/leisure activities. At Week 100, compared with BL, patients receiving 
CZP monotherapy reported on average fewer household work days missed per month 
(1.0 vs. 10.1), fewer days with reduced productivity in the home (1.1 vs. 12.1), reduced 
interference of RA on household productivity (2.0 vs. 5.8 on a 0–10 scale), fewer 
missed days of family/social/leisure activities (0.3 vs. 5.0). Improvements were seen as 
early as Week 4 and were sustained until Week 100. Over 12, 52 and 100 weeks, 
mean annualised cumulative gains from BL were 20.5, 108.4 and 199.3 household 
work days, respectively, 25.1, 136.0 and 244.9 more productive days within the 
household, and 11.9, 57.7 and 107.2 days gained of family/social/leisure activities. 
CONCLUSIONS: CZP 400 mg Q4W monotherapy provides sustained improvement 
in productivity within the home and in RA patients’ abilities to engage in family/social/
leisure activities. 
